Carl Zeiss Meditec AG

Carl Zeiss Meditec AG's next confirmed earnings release is scheduled for December 10, 2026.

As of December 31, 2025, Carl Zeiss Meditec AG has 81.67M shares outstanding.

These figures are as of December 31, 2025.

These figures cover the twelve months ended December 31, 2025. The company generates approximately 356,456.15 in revenue per employee across its workforce of 5,757.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended December 31, 2025, Carl Zeiss Meditec AG recorded 43.30M in income tax expense. That works out to an effective tax rate of 27.62, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 156.78M, leaving 112.29M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 6, 2026, Carl Zeiss Meditec AG's stock has declined approximately 75.51% over the past 52 weeks. The 50-day moving average sits at 81.99, while the 200-day moving average is 76.52.

Over the twelve months ended December 31, 2025, Carl Zeiss Meditec AG generated 2.05B in revenue and converted that into 112.29M in net income, yielding earnings per share of 1.32. EBITDA reached 182.81M, while operating income came in at 182.81M.

Carl Zeiss Meditec AG produced 235.41M in operating cash flow over the twelve months ended December 31, 2025.

Over the twelve months ended December 31, 2025, Carl Zeiss Meditec AG posted a gross margin of 52.19, reflecting its pricing power and cost economics. The operating margin of 8.91 and net profit margin of 5.47 provide insight into operational efficiency.

Carl Zeiss Meditec AG's most recent stock split took place on October 24, 2006.